What You Should Know:
– Aidoc, a leader in clinical AI, has expanded its aiOS
(AI Operating System) through a collaboration with NVIDIA MONAI and a new partnership with Quibim to solve the “last mile” deployment challenge for imaging AI.
– The ecosystem expansion allows health systems to rapidly and reliably deploy internally developed and open-source models built on MONAI directly into routine clinical workflows at scale. The move validates the need for a unified operating system that can handle the orchestration, monitoring, and governance of both commercial and homegrown AI solutions.
The AI Deployment Chasm: Aidoc Bridges the Gap Between MONAI Research and Routine Clinical Use
Imaging AI is no longer a futuristic concept; it is an imperative. Health systems are rapidly adopting commercial solutions, but a growing number of leading hospitals and academic centers are also developing their own AI models, finely tuned to local patient populations and organizational priorities.
Yet, a fundamental bottleneck persists: the “last mile” deployment challenge. Training a model is one thing; reliably and securely scaling it across multiple clinical sites, modalities, and electronic health records (EMRs) is another entirely. These internally developed models often remain “stranded,” unable to reach the patients who could benefit.
Aidoc, the global leader in clinical AI, is directly addressing this deployment chasm through a major expansion of its aiOS (AI Operating System), positioning itself as the indispensable operating layer for the entire imaging AI ecosystem.
The Aidoc-MONAI Partnership: Operationalizing Open-Source AI
The core of this expansion is a first-of-its-kind collaboration with NVIDIA MONAI, the world’s leading open-source framework for medical imaging AI, boasting nearly 500,000 downloads per month.
Through this partnership, health systems, academic labs, and research teams can connect their MONAI-based models—including those from MONAI’s Model Zoo and internal labs—directly into the Aidoc aiOS through one dedicated API.
This is a game-changer for AI development. Instead of each organization having to rebuild the infrastructure, security, monitoring, and EMR integrations required for deployment, the Aidoc aiOS provides a standardized, clinical-grade path from development to real-world impact.
“Our goal is safe, real-world clinical AI at scale,” said Tom Valent, Chief Business Officer of Aidoc. “NVIDIA’s investment in MONAI has created a global open-source community for AI development. Aidoc contributes the complementary piece: one open, clinical-grade API and an operating layer that make those models deployable and dependable in real care settings.”
Expanding the Commercial Ecosystem with Prostate MRI AI
Alongside the open-source initiative, Aidoc is strengthening its commercial offering by partnering with Quibim to introduce a best-in-class Prostate MRI AI solution. This collaboration extends Aidoc’s unified coverage across five modalities, including X-ray, CT, MR, mammography, and echocardiography.
The new solution, QP-Prostate®, dramatically enhances one of the most critical cancer detection workflows. It automatically:
- Evaluates PI-RADS v2.1 compliance.
- Assesses prostate MRI image quality based on PI-QUAL v2 guidelines.
- Segments the prostate gland and identifies regions suspicious for clinically significant prostate cancer.
The tool also provides a PI-RADS-compliant structured report that integrates the AI findings with the radiologist’s annotations, enabling faster and more accurate assessments.
“Our collaboration with Aidoc reflects a shared commitment to advancing precision imaging and embedding powerful AI technologies into clinical workflows,” said Nathan Clark, Chief Commercial Officer of Quibim.
